Applications published 5 September 2007

Ophthalmic emulsions containing prostaglandins
Novalgali Pharma 1827373*

Injectable nanoparticulate olanzapine formulations
Elan Pharma International 1827374*

System for improved percutaneous absorption of skin benefitting agents
OMP 1827375*

Visco-supplement compsn and methods
Alza 1827376*

Steroid formulation and methods of treatment using same
Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 1827378*

Formulations containing alkyl-phosphocholines using novel negative charge carriers
MPG Max-Planck-Gesellschaft zur Foerderung der Wissenschaften 1827379*

Coated drug delivery formulations
Western University of Health Sciences 1827380*

A medical product comprising a glucagon-like peptide medicament intended for pulmonary inhalation
Mederio 1827381*

Novel galenic system for active principle transport, preparation method and use
Oralance Pharma 1827382*

Pharmaceutical formulation comprising low crystallinity cellulose
Ek, Ragnar; Stromme, Maria; Mihranyan, Albert 1827383*

Directly pressed indapamide tablets with delayed release of the active substance
Merckle 1827384*

Compsn comprising a sustained release coating or matrix and an NMDA receptor antagonist, method for administration such as NMDA antagonist to a subject
Neuromolecular Pharmaceuticals 1827385*

Oral compsns for absorption of phosphorus compounds
Savica, Vincenzo 1827386*

Prolonged transit time of permeability-enhancing drug eluting pill
E-Pill Pharma 1827387*

Local delivery of drugs or substances using electronic permeability increase
E-Pill Pharma 1827388*

Sustained-release nanoparticle compsns and methods for using the same
The Board of Regents of the University of Nebraska 1827389*

Enteric film coating compsn containing enteric polymer micronised with detackifier
BPSI Holdings 1827390*

Dosage forms and methods of use thereof
Aprecia Pharmaceuticals 1827391*

Liquid, gas and/or vapour phase delivery systems
Byrd-Walsh 1827392*

Room temperature stable dronabinol formulations
Insys Therapeutics 1827393*

Protein delivery system
Bioactive Protein Delivery Therapy 1827394*

Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminogycan particles, their manufacturing and their use for diagnostics and therapy
Tel-Aviv University Future Technology Development 1827395*

Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
Flamel Technologies 1827396*

Over-dosage indicating medicated film strip
Warner-Lambert 1827397*

Transdermal, therapeutic system with activatable oversaturation and controlled permeation promotion
LTS Lohmann Therapie-Systeme 1827398*

Temperature modulation of transdermal drug delivery
Alza 1827399*

Topical skin patch containing xanthophylls
Nu-Tein 1827400*

Compsns and methods for treating conditions of the nail unit
Talima Therapeutics 1827401*

Oral formulations of desoxypeganine and uses thereof
HF Arzneimittelforschung 1827402*

Compsns for treating surface ocular pathologies
Bueno, Lionel; Droy-Lefaix, Marie-TherEse; Caron, Phillipe 1827403*

Use of alpha-adrenergic blockers for the treatment of dysmenorrhea
Boehringer Ingelheim Pharmaceuticals 1827404*

Capsaicinoid gel formulation and uses thereof
Algorx Pharmaceuticals 1827405*

Anti-radial agents
Ciba Specialty Chemicals 1827406*

Methods, assays and compsns for treating retinol-related diseases
Sirion Therapeutics 1827407*

Method for treating skin disorders with xanthophylls
Nu-Tein 1827408*

Rasagiline orally disintegrating compsns
Teva Pharmaceutical Industries 1827409*

Bis(thio-hydrazide amides) for increasing HSP70 expression
Synta Pharmaceuticals 1827410*

Diphenylurea derivatives useful as potassium channel activators
Neuroresearch 1827411*

Compsns for use in surgery
BTG International 1827412*

Use of cyclodextrin complexes containing lipoic acid
Cargill 1827413*

Use of omega-3 fatty acid(s) doe treating hypercholesterolemia caused by anti-retroviral treatment of HIV-infected patients
Pierre Fabre Medicament 1827414*

Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome
Sanofi-Aventis Deutschland 1827415*

Pharmaceutical compsns
Abbott Laboratories 1827416*

Enhanced occlusive effect photodynamic therapy
Light Sciences Corp 1827417*

Compsns including iron
Drugtech Corp 1827418*

Methods and compsns for enhancing iron absorption
Drugtech Corp 1827419*

Octahydropyrano[3,4-C]pyrrole tachykinin receptor antagonists
Merck 1827420*

Estrogen receptor modulators
Merck 1827421*

JNK inhibitors for the treatment of CNS injury
Celgene 1827422*

Novel cyclic ureas used as inhibitors of metalloproteases
Sanofi-Aventis Deutschland 1827423*

Combination therapy comprising telmisartan and hydrochlorothiazide
Boehringer Ingelheim International 1827424*

Use of PPAR agonists for the treatment of congestive heart failure
Sanofi Aventis Deutschland 1827425*

Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
Solvay Pharmaceuticals 1827426*

Aryloxyethylamine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
Solvay Pharmaceuticals 1827427*

Compsns comprising an epothilone and production methods
Bayer Schering Pharma 1827428*

Pharmaceutical compsns comprising amorphous benzimidazole compounds
Dr Reddy's Laboratories 1827429*

Nanoparticulate benzothiophene formulations
Elan Pharma International 1827430*

Methods and compsns using immuno-modulatory compounds for treatment and management of central nervous system injury
Celgene 1827431*

Inhalation medicament containing a novel anticholinesterase drug, formoterol and a steroid
Boehringer Ingelheim 1827432*

A compsn comprising at least 3 different diols
Ambria Dermatology 1827433*

Quinolines and quinazoline analogues and their use as medicaments for treating cancer
Amgen 1827434*

4-phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
AMR Technology 1827435*

Inhibition of AKT activity
Merck 1827436*

Combinations of therapeutic agents for treating cancer
Novartis 1827437*

Pyridine derivatives for inhibiting human stearoyl-CoA-desaturase
Xenon Pharmaceuticals 1827438*

Novel M3 muscarinic acetylcholine receptor antagonists
Glaxo Group 1827439*

Method for reduction, stabilisation and prevention of rupture of lipid rich plaque
Kowa 1827440*

Combination for the treatment of diseases involving cell proliferation
Boehringer Ingelheim International 1827441*

Use of diketodithiopiperazine antibiotics for the preparation of antiangiogenic pharmaceutical compsns
Cell Therapeutics Europe 1827442*

Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs
Adherex Technologies 1827443*

MNK1 or MNK2 inhibitors
DeveoGen 1827444*

Enhancing treatment of cancer and HIF-1 mediated disorders with adenosine A3 receptor antagonists
King Pharmaceuticals Research and Development 1827445*

Sulphonyl semicarbazides, semicarbazides and ureas, pharmaceutical compsns thereof, and methods for treating haemorrhagic fever viruses, including infections associated with arenaviruses
Siga Technologies 1827446*